Verastem, Inc. (VSTM) Starts Presentation at Annual Marcum MicroCap Conference

Verastem, Inc. (NASDAQ: VSTM) is focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. The company’s lead Focal Adhesion Kinase (FAK) inhibitor, VS-6063, has orphan drug designation for use in mesothelioma in the European Union and in the United States and is currently undergoing clinical trials in 12 countries worldwide. VS-6063 is also in a Phase 1b trial in combination with paclitaxel for patients with ovarian cancer, a Phase 2 study in patients with non-small cell lung cancer, and a Phase 1 trial in Japan in patients with solid tumors. For more information, visit the company’s website at www.verastem.com